Pfizer (NYSE:PFE) Shares Down 0.4% – Should You Sell?

Pfizer Inc. (NYSE:PFE) shares fell 0.4% on Wednesday . The company traded as low as $22.21 and last traded at $22.35. 8,255,824 shares were traded during mid-day trading, a decline of 83% from the average session volume of 47,947,738 shares. The stock had previously closed at $22.44.

Analyst Ratings Changes

PFE has been the subject of several research reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. UBS Group decreased their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Stock Performance

The stock has a market capitalization of $125.11 billion, a P/E ratio of 15.65, a PEG ratio of 0.64 and a beta of 0.67. The company’s fifty day simple moving average is $25.09 and its two-hundred day simple moving average is $26.31. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the previous year, the company posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

Institutional investors have recently modified their holdings of the business. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the fourth quarter worth $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the period. Finally, Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer during the 4th quarter worth about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.